1. Home
  2. Pharma & Healthcare
  3. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Status and Forecast 2021-2027

Global Age-relatedMacularDegeneration (ARMD) Drugs Market Status and Forecast 2021-2027

Publication Month: Sep 2021 | No. of Pages: 125 Published By: GRD Survey
Single User License: US $ 2980
Corporate User License: US $ 5960

This report provides a comprehensive analysis of current global Age-relatedMacularDegeneration (ARMD) Drugs market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Age-relatedMacularDegeneration (ARMD) Drugs industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Age-relatedMacularDegeneration (ARMD) Drugs market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Age-relatedMacularDegeneration (ARMD) Drugs market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Age-relatedMacularDegeneration (ARMD) Drugs Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Age-relatedMacularDegeneration (ARMD) Drugs industry.
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions

Segmented by Type
Anti VEGF Drugs
Photosensitive Drugs
Others

Segmented by Application
Exudative ARMD
Atrophy ARMD

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
TRACON Pharmaceuticals
Santen Oy
Roche
Regeneron Pharmaceuticals
Pfizer
Novartis
Kanghong Pharmaceuticals
GSK
Eli Lilly and Company
BIOCAD
Bayer


Table of Contents

1 Product Introduction and Overview
1.1 Product Definition
1.2 Product Specification
1.3 Global Market Overview
1.3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Status and Forecast (2016-2027)
1.3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value CAGR by Region
1.4 Market Drivers, Inhibitors
1.4.1 Market Drivers
1.4.2 Market Inhibitors
1.4.3 COVID-19 Impact Analysis
2 Global Age-relatedMacularDegeneration (ARMD) Drugs Supply by Company
2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Company
2.2 Age-relatedMacularDegeneration (ARMD) Drugs Sales Area of Main Manufacturers
2.3 Trend of Concentration Rate
3 Global and Regional Age-relatedMacularDegeneration (ARMD) Drugs Market Status by Type
3.1 Age-relatedMacularDegeneration (ARMD) Drugs Type Introduction
3.1.1 Anti VEGF Drugs
3.1.2 Photosensitive Drugs
3.1.3 Others
3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market by Type
3.3 North America: by Type
3.4 Europe: by Type
3.5 Asia Pacific: by Type
3.6 Central & South America: by Type
3.7 Middle East & Africa: by Type
4 Global and Regional Age-relatedMacularDegeneration (ARMD) Drugs Market Status by Application
4.1 Age-relatedMacularDegeneration (ARMD) Drugs Segment by Application
4.1.1 Exudative ARMD
4.1.2 Atrophy ARMD
4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market by Application
4.3 North America: by Application
4.4 Europe: by Application
4.5 Asia Pacific: by Application
4.6 Central & South America: by Application
4.7 Middle East & Africa: by Application
5 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Status by Region
5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market by Region
5.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Status
5.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Status
5.4 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Status
5.5 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Status
5.6 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Status
6 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Status
6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market by Country
6.2 United States
6.3 Canada
6.4 Mexico
7 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Status
7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market by Country
7.2 Germany
7.3 France
7.4 UK
7.5 Italy
7.6 Russia
7.7 Spain
8 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Status
8.1 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market by Country
8.2 China
8.3 Japan
8.4 Korea
8.5 Southeast Asia
8.6 India
8.7 Australasia
9 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Status
9.1 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market by Country
9.2 Brazil
9.3 Argentina
9.4 Colombia
10 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Status
10.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market by Country
10.2 Iran
10.3 Israel
10.4 Turkey
10.5 South Africa
10.8 Saudi Arabia
11 Major Downstream Customers Analysis
11.1 Customer One Analysis
11.2 Customer Two Analysis
11.3 Customer Three Analysis
11.4 Customer Four Analysis
12 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Type and by Application
12.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Forecast (2022-2027)
12.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Type
12.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Application
13 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Region/Country
13.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Region (2022-2027)
13.2 North America Market Forecast
13.3 Europe Market Forecast
13.4 Asia Pacific Market Forecast
13.5 Central & South America Market Forecast
13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
14.1 TRACON Pharmaceuticals
14.1.1 Company Information
14.1.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.1.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.1.4 SWOT Analysis
14.2 Santen Oy
14.2.1 Company Information
14.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.2.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.2.4 SWOT Analysis
14.3 Roche
14.3.1 Company Information
14.3.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.3.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.3.4 SWOT Analysis
14.4 Regeneron Pharmaceuticals
14.4.1 Company Information
14.4.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.4.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.4.4 SWOT Analysis
14.5 Pfizer
14.5.1 Company Information
14.5.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.5.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.5.4 SWOT Analysis
14.6 Novartis
14.6.1 Company Information
14.6.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.6.4 SWOT Analysis
14.7 Kanghong Pharmaceuticals
14.7.1 Company Information
14.7.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.7.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.7.4 SWOT Analysis
14.8 GSK
14.8.1 Company Information
14.8.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.8.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.8.4 SWOT Analysis
14.9 Eli Lilly and Company
14.9.1 Company Information
14.9.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.9.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.9.4 SWOT Analysis
14.10 BIOCAD
14.10.1 Company Information
14.10.2 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction
14.10.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
14.10.4 SWOT Analysis
14.11 Bayer
15 Conclusion
16 Methodology

Tables and Figures

List of Tables

Table Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) and CAGR by Region (2016-2027)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Company (2019-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Company (2019-2021)
Table Main Manufacturers Age-relatedMacularDegeneration (ARMD) Drugs Sales Area
Table Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration (Top 3, Top 5) (2019-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Type (2016-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Sals Value Market Share by Type (2016-2021)
Table North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Type (2016-2021)
Table North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Type (2016-2021)
Table Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Type (2016-2021)
Table Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Type (2016-2021)
Table Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Type (2016-2021)
Table Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Type (2016-2021)
Table Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Type (2016-2021)
Table Central & South America Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Type (2016-2021)
Table Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Type (2016-2021)
Table Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Type (2016-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Application (2016-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Application (2016-2021)
Table North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Application (2016-2021)
Table North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Application (2016-2021)
Table Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Application (2016-2021)
Table Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Application (2016-2021)
Table Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Application (2016-2021)
Table Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Application (2016-2021)
Table Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Application (2016-2021)
Table Central & South America Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Application (2016-2021)
Table Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Application (2016-2021)
Table Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Application (2016-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Region (2016-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Region (2016-2021)
Table North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Country (2016-2021)
Table North America Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Country (2016-2021)
Table Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Country (2016-2021)
Table Europe Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Country (2016-2021)
Table Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Country (2016-2021)
Table Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Country (2016-2021)
Table Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Country (2016-2021)
Table Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Country (2016-2021)
Table Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (Million USD) by Country (2016-2021)
Table Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Country (2016-2021)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value (Million USD) Forecast by Type (2022-2027)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share Forecast by Type (2022-2027)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value (Million USD) Forecast by Application (2022-2027)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share Forecast by Application (2022-2027)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value (Million USD) Forecast by Region (2022-2027)
Table Global Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share Forecast by Region (2022-2027)
Table TRACON Pharmaceuticals Company Information
Table TRACON Pharmaceuticals Product Introduction
Table TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table Santen Oy Company Information
Table Santen Oy Product Introduction
Table Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table Roche Company Information
Table Roche Product Introduction
Table Roche Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table Regeneron Pharmaceuticals Company Information
Table Regeneron Pharmaceuticals Product Introduction
Table Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table Pfizer Company Information
Table Pfizer Product Introduction
Table Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table Novartis Company Information
Table Novartis Product Introduction
Table Novartis Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table Kanghong Pharmaceuticals Company Information
Table Kanghong Pharmaceuticals Product Introduction
Table Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table GSK Company Information
Table GSK Product Introduction
Table GSK Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table Eli Lilly and Company Company Information
Table Eli Lilly and Company Product Introduction
Table Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)
Table BIOCAD Company Information
Table BIOCAD Product Introduction
Table BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, Gross Margin and Global Share (2019-2021)


Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets